Allergy and Asthma Proceedings

Papers
(The TQCC of Allergy and Asthma Proceedings is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Hereditary angioedema: Epidemiology and burden of disease66
Long COVID: A proposed hypothesis-driven model of viral persistence for the pathophysiology of the syndrome45
The global burden of vaccine-preventable infectious diseases in children less than 5 years of age: Implications for COVID-19 vaccination. How can we do better?44
COVID-19 in children: Pathogenesis and current status31
Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-231
Definition and classification of hereditary angioedema29
Triggers and short-term prophylaxis in patients with hereditary angioedema28
Delayed systemic urticarial reactions following mRNA COVID-19 vaccination27
Treatment strategies for postviral olfactory dysfunction: A systematic review25
Patient perspectives on the treatment burden of injectable medication for hereditary angioedema25
COVID-19 in a patient with severe asthma using mepolizumab23
Clinical presentation of hereditary angioedema23
Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH)22
Hereditary angioedema: Special considerations in women21
Safety and efficacy of direct two-step penicillin challenges with an inpatient pharmacist-driven allergy evaluation21
Hereditary angioedema: On-demand treatment of angioedema attacks20
Does aeroallergen sensitivity and allergic rhinitis in children cause milder COVID-19 infection?19
Hereditary angioedema and shared decision making19
Hereditary angioedema: Differential diagnosis, diagnostic tests, and family screening19
The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome19
Effect of COVID-19 on hereditary angioedema activity and quality of life18
Hereditary angioedema: Special considerations in children18
Psychology and hereditary angioedema: A systematic review18
Outcomes among patients with COVID-19 and asthma: A systematic review and meta-analysis18
Salivary and serum IgA and IgG responses to SARS-CoV-2-spike protein following SARS-CoV-2 infection and after immunization with COVID-19 vaccines17
Hereditary angioedema: Long-term prophylactic treatment17
Eosinopenia could be a relevant prognostic biomarker in patients with coronavirus disease 201917
Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies17
The role of the allergist/immunologist in the COVID-19 pandemic: A Janus-faced presentation16
Androgen use in hereditary angioedema: A critical appraisal and approaches to transitioning from androgens to other therapies16
COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications15
Sustained decrease in pediatric asthma emergency visits during the first year of the COVID-19 pandemic15
Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study15
Long-term efficacy of injected allergen immunotherapy for treatment of grass pollen allergy in elderly patients with allergic rhinitis15
Intralymphatic immunotherapy for allergic rhinitis: A systematic review and meta-analysis15
Allergic reactions and adverse events associated with administration of mRNA-based vaccines. A health-care system experience15
Assessing the cost and quality-of-life impact of on-demand‐only medications for adults with hereditary angioedema15
Treg‐inducing capacity of genomic DNA of Bifidobacterium longum subsp. infantis15
COVID-19 vaccines and vaccine hesitancy: Role of the allergist/immunologist in promotion of vaccine acceptance15
Shifts in allergy practice in a COVID-19 world: Implications of pre‐COVID-19 national health care provider and patient surveys of treatments for nasal allergies15
Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base14
Psychological burden of COVID-19 on mild and moderate chronic spontaneous urticaria14
Long-term efficacy of the sublingual and subcutaneous routes in allergen immunotherapy14
Tropomyosin: A panallergen that causes a worldwide allergic problem14
Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs14
Hereditary angioedema: Investigational therapies and future research13
Hereditary angioedema: Comprehensive management plans and patient support13
COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol13
Successful treatment of coronavirus disease 2019 in a patient with asthma13
Treatment options for chronic rhinosinusitis with nasal polyps13
Atopic dermatitis: Correlation of severity with allergic sensitization and eosinophilia12
Accelerated/rush allergen immunotherapy12
Safety of subcutaneous allergen immunotherapy12
Recurrent and acute abdominal pain as the main clinical manifestation in patients with hereditary angioedema12
Coronavirus disease 2019, allergic diseases, and allergen immunotherapy: Possible favorable mechanisms of interaction12
Visceral obesity is associated with clinical and inflammatory features of asthma: A prospective cohort study11
Phenotypes and natural history of food protein‐induced enterocolitis syndrome in the east Mediterranean region11
Novel diagnostic techniques and therapeutic strategies for IgE‐mediated food allergy11
Global perceptions of the current and future impacts of COVID-19 on hereditary angioedema management11
Shrimp and cockroach co-sensitization in Southern China: Association with moth sensitization11
Caregivers’ role in managing hereditary angioedema and perceptions of treatment-related burden11
Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations11
Weighing the benefits and risks of oral immunotherapy in clinical practice10
Serum levels of specific immunoglobulin E toDermatophagoides pteronyssinusallergen components in patients with allergic rhinitis or/and asthma10
Efficacy and safety of sublingual allergen immunotherapy10
Allergy immunotherapy: Future directions for the 2020s10
Delayed allergic skin reactions to vaccines9
Evaluation of drug patch tests in children9
Considerations for asthma management and viral transmission in the era of COVID-199
Adherence and usage patterns of inhaled corticosteroids‐long-acting beta-agonists by using inhaler-monitoring technology9
Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease9
Long-term prophylaxis in hereditary angioedema management: Current practices in France and unmet needs9
Idiopathic anaphylaxis: Diagnosis and management9
Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis9
COVID-19 pandemic impact on telehealth use and perceptions for atopic and respiratory disease: Survey results9
How important is proper dosing for subcutaneous and sublingual allergy immunotherapy?8
Analysis of the long-term efficacy and safety of subcutaneous immunotherapy for atopic dermatitis8
Allergy to oak pollen in North America8
Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria8
Short-term prophylaxis for children and adolescents with hereditary angioedema8
The long COVID syndrome: A conundrum for the allergist/immunologist8
Association between asthma symptom scores and perceived stress and trait anxiety in adolescents with asthma8
Association between elevated serum triglycerides and asthma in patients with obesity: An explorative study8
Epinephrine autoinjector prescription filling after pediatric emergency department discharge8
Patient perspectives on penicillin allergy and testing7
Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose7
Nasal reactivity evaluation in children with allergic rhinitis receiving grass pollen sublingual immunotherapy7
Asthma in pregnancy7
Real-world cohort study of adult and pediatric patients treated for hereditary angioedema in the United States7
Add-on tiotropium versus step-up inhaled corticosteroid plus long-acting beta-2‐agonist in real-world patients with asthma7
COVID-19 in Italian children and adolescents: The role of allergy and asthma7
Eosinophil-derived neurotoxin: An asthma exacerbation biomarker in children7
A 2-year-old girl with periprocedural anaphylaxis7
An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial7
A 48-year-old female with perioperative anaphylaxis7
Patients' and physicians' attitudes and perception about asthma in the Gulf: A subset analysis from the Asthma Insights and Management Survey in the Gulf and Russia7
0.022234916687012